bupropion has been researched along with D-fructopyranose in 32 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (28.13) | 29.6817 |
| 2010's | 22 (68.75) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Kennedy, SH; Mancini, DA; McCann, S; McIntyre, RS; Sagman, D; Srinivasan, J | 1 |
| Li, Z; Maggard, M; Maglione, M; Mojica, WA; Morton, SC; Shekelle, PG; Shugarman, L; Solomon, V; Suttorp, M; Tu, W | 1 |
| Carter, GT; Han, JJ; McCrory, MA; Yudkowsky, MP | 1 |
| Geddes, J; Macritchie, K; Vasudev, K; Watson, S; Young, A | 1 |
| Ait-Daoud, N; Breland, AB; Johnson, BA; Lynch, WJ; Marzani-Nissen, GR; Penberthy, JK | 1 |
| Dannon, PN; Gonopolsky, Y; Kotler, M; Lowengrub, K; Musin, E | 1 |
| Al-Zaman, Y; Aylwin, S | 1 |
| Bras, M | 1 |
| Kapoor, S | 1 |
| Bańka, K; Barczyński, B; Buszewicz, G; Mądro, R; Mróz, T; Tutaj, K; Tutka, P; Wielosz, M; Łuszczki, JJ | 1 |
| Bray, GA; Ryan, DH | 1 |
| Goldfine, AB; Hiatt, WR; Thomas, A | 1 |
| Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J | 1 |
| Howland, RH | 1 |
| Nakazato, M; Ueno, H | 1 |
| Aldhoon-Hainerová, I; Hainer, V | 1 |
| Hainer, V | 1 |
| Cunningham, JW; Wiviott, SD | 1 |
| Goutier, W; Kloeze, M; McCreary, AC | 1 |
| Citrome, L | 1 |
| Rubio, MA | 1 |
| Mehr, SR; Zimmerman, MP | 1 |
| Dahiya, N; Kakkar, AK | 1 |
| Fujioka, K | 1 |
| McCall, WV; Rosenquist, PB; Surya, S | 1 |
| Bragg, R; Crannage, E | 1 |
| Etminan, M; Mikelberg, FS; Symes, RJ | 1 |
| Megyeri, J; Nuffer, W; Trujillo, JM | 1 |
| Halpern, B; Mancini, MC | 1 |
| Aronne, LJ; Igel, LI; Kumar, RB; Saunders, KH | 1 |
| Curry, SA | 1 |
| Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S | 1 |
16 review(s) available for bupropion and D-fructopyranose
| Article | Year |
|---|---|
Pharmacological and surgical treatment of obesity.
Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric Bypass; Gastroplasty; Humans; Lactones; Lipase; Obesity; Orlistat; Phentermine; Topiramate | 2004 |
Topiramate for acute affective episodes in bipolar disorder.
Topics: Affective Disorders, Psychotic; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Disorder; Fructose; Humans; Randomized Controlled Trials as Topic; Topiramate | 2006 |
Treating smoking dependence in depressed alcoholics.
Topics: Alcoholism; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Depressive Disorder; Fructose; Humans; Nicotine; Psychotherapy, Group; Smoking Cessation; Topiramate | 2006 |
Emerging concepts in the medical and surgical treatment of obesity.
Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide | 2008 |
[Psychopharmacotherapy in psychiatric comorbidities among patients with chronic pain].
Topics: Amines; Analgesics; Anticonvulsants; Bupropion; Chronic Disease; Cyclohexanecarboxylic Acids; Dopamine Uptake Inhibitors; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Lamotrigine; Mental Disorders; Pain; Topiramate; Triazines | 2007 |
Recent advancements in drug treatment of obesity.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss | 2012 |
[Cutting-edge of medicine; the prospects of novel anti-obesity drugs].
Topics: Anti-Obesity Agents; Appetite; Appetite Depressants; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drug Discovery; Energy Metabolism; Enzyme Inhibitors; Fructose; Glucagon-Like Peptide 1; Humans; Hypothalamus; Lactones; Lipase; Liraglutide; Metabolic Syndrome; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate | 2014 |
Tolerability and safety of the new anti-obesity medications.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse Reactions; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate | 2014 |
Overview of new antiobesity drugs.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2014 |
Modern obesity pharmacotherapy: weighing cardiovascular risk and benefit.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cardiovascular Diseases; Clinical Trials as Topic; Drug Combinations; Fructose; Heart; Humans; Naltrexone; Obesity; Phentermine; Topiramate | 2014 |
Drug treatment of obesity: current status and future prospects.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Drug Combinations; Drug Therapy, Combination; Fructose; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate | 2015 |
Safety and tolerability of medications approved for chronic weight management.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss | 2015 |
A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2016 |
Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate | 2017 |
Practical Use of Pharmacotherapy for Obesity.
Topics: Androgens; Anti-Obesity Agents; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Appetite Depressants; Benzazepines; Bupropion; Drug Combinations; Fructose; Humans; Hypoglycemic Agents; Hypogonadism; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Testosterone; Topiramate; Weight Gain | 2017 |
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet, Reducing; Drug Combinations; Female; Fructose; Humans; Hypertension; Lactones; Male; Middle Aged; Naltrexone; Orlistat; Phentermine; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Safety-Based Drug Withdrawals; Time; Topiramate | 2021 |
1 trial(s) available for bupropion and D-fructopyranose
| Article | Year |
|---|---|
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study.
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fructose; Humans; Male; Middle Aged; Psychiatric Status Rating Scales; Single-Blind Method; Topiramate; Treatment Outcome | 2002 |
15 other study(ies) available for bupropion and D-fructopyranose
| Article | Year |
|---|---|
Topiramate for weight reduction in Duchenne muscular dystrophy.
Topics: Adolescent; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Bupropion; Caloric Restriction; Dose-Response Relationship, Drug; Drug Administration Schedule; Fructose; Humans; Male; Muscular Dystrophy, Duchenne; Obesity; Topiramate; Treatment Outcome | 2005 |
12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.
Topics: Adolescent; Adult; Analysis of Variance; Bupropion; Delayed-Action Preparations; Drug Therapy; Fluvoxamine; Follow-Up Studies; Fructose; Gambling; Humans; Israel; Male; Middle Aged; Naltrexone; Outcome Assessment, Health Care; Psychiatric Status Rating Scales; Psychopharmacology; Recurrence; Reproducibility of Results; Surveys and Questionnaires; Time Factors; Topiramate | 2007 |
Strategies to control antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; Fructose; Humans; Hypoglycemic Agents; Melatonin; Metformin; Obesity; Topiramate; Treatment Outcome; Weight Gain | 2008 |
Low dose of bupropion significantly enhances the anticonvulsant activity of felbamate, lamotrigine and topiramate in mice.
Topics: Animals; Anticonvulsants; Brain; Bupropion; Dopamine Uptake Inhibitors; Dose-Response Relationship, Drug; Drug Synergism; Electroshock; Felbamate; Fructose; Injections, Intraperitoneal; Lamotrigine; Male; Mice; Motor Activity; Phenylcarbamates; Propylene Glycols; Psychomotor Performance; Rotarod Performance Test; Seizures; Topiramate; Triazines | 2011 |
Drug treatment of obesity.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms | 2011 |
What cost weight loss?
Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss | 2012 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined Modality Therapy; Diet, Reducing; Disease Models, Animal; Drug Combinations; Exercise; Fructose; Humans; Mood Disorders; Naltrexone; Obesity; Overweight; Phentermine; Psychotic Disorders; Randomized Controlled Trials as Topic | 2013 |
Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids.
Topics: Acamprosate; Analysis of Variance; Animals; Antidiuretic Hormone Receptor Antagonists; Bupropion; Dose-Response Relationship, Drug; Fructose; Indoles; Male; Motor Activity; Naltrexone; Nicotine; Nicotinic Agonists; Pyrrolidines; Rats, Wistar; Taurine; Tobacco Use Cessation Devices; Topiramate | 2016 |
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out.
Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss | 2014 |
Pharmacological treatment of obesity in Europe: waiting for the arrival of the white blackbird.
Topics: Anti-Obesity Agents; Appetite Depressants; Benzazepines; Bupropion; Clinical Trials as Topic; Drug Approval; Drug Combinations; Europe; Fructose; Humans; Naltrexone; Obesity; Phentermine; Product Surveillance, Postmarketing; Topiramate; United States; United States Food and Drug Administration | 2014 |
Nonincretin drugs in later-stage development.
Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Drug Labeling; Drugs, Investigational; Fructose; Humans; Naltrexone; Obesity; Phentermine; United States; United States Food and Drug Administration | 2014 |
Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depression in a Patient With an Intracranial Space-Occupying Lesion: A Case Report of Safety.
Topics: Anticonvulsants; Antidepressive Agents, Second-Generation; Brain Neoplasms; Bupropion; Depressive Disorder, Major; Female; Fructose; Humans; Magnetic Resonance Imaging; Middle Aged; Pinealoma; Recurrence; Topiramate; Transcranial Magnetic Stimulation | 2016 |
Review of pharmacotherapy options for the management of obesity.
Topics: Benzazepines; Bupropion; Disease Management; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; United States | 2016 |
Risk of angle-closure glaucoma with bupropion and topiramate.
Topics: Adolescent; Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Databases, Factual; Esomeprazole; Female; Fructose; Glaucoma, Angle-Closure; Humans; Intraocular Pressure; Male; Middle Aged; Odds Ratio; Proton Pump Inhibitors; Retrospective Studies; Risk Factors; Tonometry, Ocular; Topiramate; Young Adult | 2015 |
Obesity Epidemic: Pharmaceutical Weight Loss.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss | 2017 |